Compositions having enhanced cannabicyclol (CBL) or CBL derivative concentrations are disclosed herein as are methods of synthesizing CBL and CBL derivative in high-purity form. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid extracts, isolates and/or distillates; (iii) provide CBL and/or CBL derivative at higher yield; (iv) provide easier methods to purify product mixtures comprising CBL and/or CBL derivative; (v) provide product mixtures that comprise unique ratios of CBL or CBL derivative relative to other cannabinoids; (vi) provide product mixtures with reduced THC concentrations and/or (vii) provide artificial resins having of a mixture cannabinoids that cannot be produced by extracting cannabis plant material.

The present invention provides, inter alia, a process for producing a compound of formula (I) wherein the substituents are as defined in claim 1, comprising reacting a compound of formula (II) in a suitable reaction medium comprising a desulfurization agent formula (II). The present invention further provides intermediate compounds utilised in said process, and methods for producing said intermediate compounds.

##STR00001##

The present invention provides, inter alia, a process for producing a compound of formula (I) wherein the substituents are as defined in claim 1, comprising reacting a compound of formula (II) in a suitable reaction medium comprising a desulfurization agent formula (II). The present invention further provides intermediate compounds utilised in said process, and methods for producing said intermediate compounds.

##STR00001##

Compositions having enhanced cannabicitran concentrations and/or enhanced cannabicitran-derivative concentrations are disclosed herein as are methods of synthesizing cannabicitran and/or cannabicitran derivatives. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid isolates and/or distillates; (iii) provide cannabicitran and/or cannabicitran derivatives at higher yield; (iv) provide easier to purify product mixtures comprising cannabicitran and/or cannabicitran derivatives; (v) provide product mixtures comprising cannabicitran or cannabicitran derivatives that are easier to purify; (vi) provide product mixtures that comprise unique ratios of cannabicitran or cannabicitran derivatives relative to other cannabinoids; and/or (vii) provide product mixtures with reduced THC concentrations.

Compositions having enhanced cannabicitran concentrations and/or enhanced cannabicitran-derivative concentrations are disclosed herein as are methods of synthesizing cannabicitran and/or cannabicitran derivatives. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid isolates and/or distillates; (iii) provide cannabicitran and/or cannabicitran derivatives at higher yield; (iv) provide easier to purify product mixtures comprising cannabicitran and/or cannabicitran derivatives; (v) provide product mixtures comprising cannabicitran or cannabicitran derivatives that are easier to purify; (vi) provide product mixtures that comprise unique ratios of cannabicitran or cannabicitran derivatives relative to other cannabinoids; and/or (vii) provide product mixtures with reduced THC concentrations.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

A benzene compound is prepared by reacting a furan compound to produce an unsaturated bicyclic ether having an unsaturated carbon-carbon bond; hydrogenating the unsaturated carbon-carbon bond in the unsaturated bicyclic ether to produce a saturated bicyclic ether; and dehydrating and aromatizing the saturated bicyclic ether to produce the benzene compound.

A benzene compound is prepared by reacting a furan compound to produce an unsaturated bicyclic ether having an unsaturated carbon-carbon bond; hydrogenating the unsaturated carbon-carbon bond in the unsaturated bicyclic ether to produce a saturated bicyclic ether; and dehydrating and aromatizing the saturated bicyclic ether to produce the benzene compound.

A carboxylic acid onium salt of formula (1) exerts a satisfactory acid diffusion control (or quencher) function. A resist composition comprising the carboxylic acid onium salt can be processed by DUV or EUV lithography to form a resist pattern with improved resolution, reduced LWR and minimal defects after development.

##STR00001##

A carboxylic acid onium salt of formula (1) exerts a satisfactory acid diffusion control (or quencher) function. A resist composition comprising the carboxylic acid onium salt can be processed by DUV or EUV lithography to form a resist pattern with improved resolution, reduced LWR and minimal defects after development.

##STR00001##